Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
Globe Newswire•14/10/2026•16:30 ET
0
Key Highlights
- ➤Coherus will release interim tagmokitug clinical data on October 28, 2026
- ➤Tagmokitug is being evaluated with toripalimab in multiple solid tumors
- ➤Webcast runs from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time
- ➤Tagmokitug is in Phase 1b/2a studies for advanced solid tumors
REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced that the Company will release interim clinical data related to its tagmokitug development program evaluating the cytolytic CCR8 antibody with toripalimab and multiple solid tumors on Wednesday, October 28, 2026. Coherus management will host a webcast from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time to discuss the data and provide additional context. The company has invited key opinion leaders to join the webcast and provide their clinical perspective.
When: Wednesday, October 28, 2026, from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time.
Get started
Create a free account to read the full story.